CSIMarket
 
Syndax Pharmaceuticals Inc   (SNDX)
Other Ticker:  
 
 
Price: $23.5200 $0.87 3.841%
Day's High: $23.73 Week Perf: -0.21 %
Day's Low: $ 22.43 30 Day Perf: 6.96 %
Volume (M): 3,570 52 Wk High: $ 25.34
Volume (M$): $ 83,964 52 Wk Avg: $19.30
Open: $22.58 52 Wk Low: $11.22



 Market Capitalization (Millions $) 1,643
 Shares Outstanding (Millions) 70
 Employees 38
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -176
 Cash Flow (TTM) (Millions $) 23
 Capital Exp. (TTM) (Millions $) 0

Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that specializes in developing novel therapies for a range of cancer indications. The company was founded in 2005 and is headquartered in Waltham, Massachusetts, USA.

Syndax Pharmaceuticals' lead candidate, Entinostat, is a selective histone deacetylase (HDAC) inhibitor that has shown promising results in clinical trials for the treatment of advanced breast cancer, non-small cell lung cancer (NSCLC), and other solid tumors. Entinostat works by inhibiting HDAC activity, which allows for the epigenetic reprogramming of cancer cells and the induction of tumor cell death. Syndax Pharmaceuticals is also developing a pipeline of other potentially groundbreaking therapies for cancer, including SNDX-6352, which is a monoclonal antibody targeting the colony stimulating factor 1 receptor (CSF1R) and has demonstrated strong anti-tumor activity in preclinical models.

Syndax Pharmaceuticals is committed to developing innovative treatments for cancer patients and has a strong team of scientists, researchers, and executives who are dedicated to making a difference in the lives of patients. The company has received numerous awards and recognitions for its cutting-edge work in the field of oncology, including being named a "Best Place to Work" by the Boston Business Journal and a "Top 10 Breakthrough Technology" by MIT Technology Review.

In addition to its clinical development programs, Syndax Pharmaceuticals is also focused on building strategic partnerships with other companies in the biopharmaceutical industry. The company has established collaborations with several leading academic institutions and pharmaceutical companies, including Merck, Pfizer, and AstraZeneca, to advance the development of its pipeline of therapeutic candidates.

Overall, Syndax Pharmaceuticals is a dynamic and innovative company that is poised to make a significant impact in the field of oncology. With a strong track record of scientific and clinical success, a talented team of professionals, and a commitment to advancing the cause of cancer research and treatment, Syndax Pharmaceuticals is well-positioned to continue making important contributions to the fight against cancer for years to come.


   Company Address: 35 Gatehouse Drive Waltham 2451 MA
   Company Phone Number: 419-1400   Stock Exchange / Ticker: NASDAQ SNDX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc Faces Rising Expenditures, Creating Questions for Shareholders



Syndax Pharmaceuticals Inc (SNDX) is a biopharmaceutical company that has captured the attention of market watchers with its recent financial performance. As the fiscal year comes to a close, shareholders are eagerly monitoring the company's operating deficit and anticipating new business strategies to drive future growth. The upcoming financial earnings report on February 27, 2024, carries significant weight for the shareholders, as they remain vigilant about potential adjustments to revenues.
Operating Deficit Raises Concerns
During the earnings cycle from July to September 30, 2023, SNDX experienced an operating deficit of -$56.355 million. This figure has undoubtedly raised concerns among stockholders, who are closely monitoring the company's financial health. Although no significant adjustments to revenue are anticipated, the focus remains on SNDX's ability to turn around its operating deficit into profitability.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc Faces Unexpected Downturn in Q2 2023 Financials: A Deep Dive into What This Means for Shareholders

Syndax Pharmaceuticals Inc, a pharmaceutical company known for developing innovative cancer therapies, has recently reported its financial performance for the April to June 30 2023 reporting cycle. Although the shareholders did not anticipate any changes in revenue, they closely monitored the company's operating deficit during the same period, which stood at $-49.678 million.
However, despite concerns about the company's current efficiency, the markets seem less worried and are more focused on the upcoming business strategy of Syndax Pharmaceuticals Inc. Stakeholders eagerly await further details, hoping for a successful plan to be unveiled as soon as possible.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com